[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"intestinal-permeability\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:intestinal-permeability":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,53,85],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100643167","evaluation-of-metabolic-parameters-intestinal-permeability-and-gastrointestinal-symptoms-after-bariatric-surgery-in-body-weight-management-100643167",false,"NCT07643376","Evaluation of Metabolic Parameters, Intestinal Permeability and Gastrointestinal Symptoms After Bariatric Surgery in Body Weight Management","Evaluation of Postoperative Metabolic Parameters, Intestinal Permeability and Gastrointestinal Symptoms in Body Weight Management After Laparoscopic Sleeve Gastrectomy","METABAR","Inclusion Criteria:\n\n* Underwent Laparoscopic Sleeve Gastrectomy (LSG) within the last 1 month\n* Aged between 19-50 years\n* BMI ≥40 kg\u002Fm² or BMI ≥35 kg\u002Fm² with obesity-related comorbidities\n* Signed informed consent form\n* Non-smoker and non-alcohol dependent\n\nExclusion Criteria:\n\n* Did not undergo or is not planned to undergo LSG\n* Outside the age range of 19-50 years\n* Did not sign the informed consent form\n* BMI \\\u003C40 kg\u002Fm² or BMI \\\u003C35 kg\u002Fm² without obesity-related comorbidities\n* Smoker or alcohol dependent\n* Has an inflammatory disease\n* Currently using probiotics, antibiotics, or fiber supplements\n* Has a psychiatric disorder","ALL","19 Years","50 Years",{"count":21,"type":22},40,"ESTIMATED","OBSERVATIONAL","This study aims to evaluate the changes in metabolic parameters, intestinal permeability, and gastrointestinal symptoms in individuals who have undergone bariatric surgery (Laparoscopic Sleeve Gastrectomy - LSG) for obesity treatment.\n\nObesity is a chronic disease associated with serious health complications including type 2 diabetes, hypertension, cardiovascular disease, and metabolic disorders. Bariatric surgery is currently the most effective treatment method for morbid obesity. However, monitoring patients after surgery in terms of metabolic health, gut permeability, and gastrointestinal symptoms is crucial for long-term success.\n\nIn this study, 40 volunteers (aged 19-50) who have undergone LSG surgery within the last month will be followed for 6 months. At the beginning of the study and 6 months later, the following will be assessed:\n\n* Metabolic parameters: fasting blood glucose, total cholesterol, triglycerides, high-density lipoprotein (HDL), low-density lipoprotein (LDL), very low-density lipoprotein (VLDL) cholesterol, and insulin levels\n* Intestinal permeability markers: zonulin, secretory immunoglobulin A (IgA), and lipopolysaccharide (LPS) levels\n* Gastrointestinal symptoms: assessed using the Gastrointestinal Symptom Rating Scale (GSRS)\n* Anthropometric measurements: body weight, height, waist and hip circumference, BMI\n* Nutritional intake: 3-day dietary records\n\nThe study will be conducted at Bursa Yıldırım Doruk Hospital, General Surgery Clinic. Results will contribute to understanding the relationship between bariatric surgery and gut health, potentially helping to prevent postoperative complications.",[26,27,28,29,30],"Obesity, Morbid","Bariatric Surgery","Intestinal Permeability","Gastrointestinal Symptoms","Metabolic Syndrome",[32,33,34,35,36,37,38,39],"Laparoscopic Sleeve Gastrectomy","Zonulin","Secretory IgA","Lipopolysaccharide","GSRS","Body Weight Management","Gut microbiota","Postoperative Metabolic Parameters","NOT_YET_RECRUITING","2026-06-08",{"date":43,"type":44},"2026-06-11","ACTUAL",{"date":46,"type":22},"2026-07-01",{"date":48,"type":22},"2027-02-01",{"name":50,"class":51},"Toros University","OTHER",1,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":61,"enrollmentInfo":62,"targetDuration":4,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":71,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":83,"locationsCount":4},"100621489","administration-of-fiber-as-a-dietary-supplement-to-improve-the-management-of-alcohol-withdrawal-100621489","NCT07371286","Administration of Fiber as a Dietary Supplement to Improve the Management of Alcohol Withdrawal","Administration of Fiber as a Dietary Supplement to Improve the Management of Alcohol Withdrawal - Randomized Controlled Open-label Study - FIB-ALC","FIB-ALC","Inclusion Criteria:\n\n* Women or men,\n* aged \\>18 and ≤ 65,\n* French-speaking,\n* active alcohol users (as defined by the criteria in the Diagnostic and Statistical Manual of Mental Disorders, 5th edition, DSM-5)\n* who agree to be hospitalized for alcohol withdrawal for a period of 7 days\n* Affiliated with or eligible for social security.\n* Negative pregnancy test (for patients of childbearing age)\n\nExclusion Criteria:\n\n* any other addictive disorder (except tobacco),\n* inflammatory bowel disease or any other chronic inflammatory disease,\n* current cancer,\n* metabolic diseases such as obesity (BMI ≥ 30 kg\u002Fm²) kg\u002Fm2) or a history of bariatric surgery,\n* severe cognitive impairment (MMSE \\\u003C 24),\n* psychiatric comorbidities including suicide risk,\n* cirrhosis or significant fibrosis (≥F2) defined by a Fibroscan value \\>7.6 kPa,\n* pregnancy or breastfeeding,\n* taking antibiotics, probiotics, or prebiotics in the 2 months prior to inclusion,\n* taking non-steroidal anti-inflammatory drugs or glucocorticoids in the month prior to inclusion.\n* taking baclofen, disulfiram, naltrexone, or acamprosate.\n* Participation in another interventional study involving human subjects or being in the exclusion period following a previous study involving human subjects, if applicable\n* Patients under AME\n* Patients under guardianship, trusteeship, or any other legal protection measure","65 Years",{"count":63,"type":22},138,"INTERVENTIONAL",[66],"NA","The goal of this clinical trial is to demonstrate that a fiber-enriched diet (with a high proportion of inulin and pectin) combined with standard care can reduce intestinal permeability in patients with alcohol use disorder (AUD) aged between 19 and 65.\n\nThe hypothesis of our study is that a diet rich in different dietary fibers (mainly inulin and pectin), by modifying the gut microbiota and its metabolites, will induce a decrease in intestinal permeability, restore the composition of the gut microbiota and its metabolites, and further improve abstinence, levels of craving and anxiety, inflammation, steatosis, and hepatic fibrosis in patients with alcohol use disorder.\n\nThe study consists of two parallel groups (a group eating fiber-rich snacks every day for 28 days (in addition to their usual care) versus a group not eating any snacks).\n\nParticipants will be required to provide stool, blood, and saliva samples, and complete questionnaires.",[69,70,28],"Alcohol Use Disorder","Supplementation",[72,73,74,75,76],"Alcohol","Dietary fibers","Food supplementation","Intestinal permeability","Misuse","2026-01-19",{"date":79,"type":44},"2026-01-27",{"date":81,"type":22},"2026-02",{"date":81,"type":22},{"name":84,"class":51},"Assistance Publique - Hôpitaux de Paris",{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":92,"sex":17,"minAge":93,"maxAge":61,"enrollmentInfo":94,"targetDuration":4,"studyType":64,"phases":96,"briefSummary":97,"conditions":98,"keywords":100,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":52},"100574522","dietary-supplements-for-reduction-of-intestinal-permeability-levels-100574522","NCT06760377","Dietary Supplements for Reduction of Intestinal Permeability Levels","permeability","Inclusion Criteria:\n\n* Subjects between 18 and 65 years of age with elevated levels of zonulin in stool (greater than 80 ng\u002Fml).\n\nExclusion Criteria:\n\n* Taking any type of antibiotic in the last month\n* Taking prebiotics or probiotics products in the last month.\n* Taking laxatives in the last month.\n* Undergoing any medicinal treatment\n* Pregnancy\n* Subject with a history of current gastrointestinal pathology or disorder such as: acute colon pathology, acute haemorrhagic colitis, suspected digestive perforation, recent abdominal surgery, severe arterial hypertension, abdominal hernia, colon neoplasia, history of cardiac syncope, renal failure, liver cirrhosis, epilepsy, severe psychiatric illness (psychosis), necrosis due to abdominal irradiation, severe anaemia, severe neurovegetative lability.",true,"18 Years",{"count":95,"type":22},85,[66],"A randomised and controlled trial, in which the effect of a dietary supplement is evaluated for reduction of intestinal permeability levels of subjects with high levels of zonulin in feces",[28,99,33],"Leaky Gut Syndrome",[101,102,103,104],"intestinal permeability","leaky gut syndrome","zonulin","tight junctions","2024-12-29",{"date":107,"type":44},"2025-01-06",{"date":109,"type":22},"2025-02-01",{"date":111,"type":22},"2025-06-01",{"name":113,"class":51},"Universidad Complutense de Madrid"]